Invivo therapeutics holdings corp. (NVIV)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Net loss

-

-

-

-

-

-18,346

-

-

-

Cash flows from operating activities:
Net loss

-11,830

-23,423

-26,745

-23,438

-33,314

-

-

-

-

Net loss

-

-

-

-

-

-

-38,756

4,664

-34,728

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

57

91

395

548

684

752

740

367

144

Amortization of operating lease right-of-use assets

265

-

-

-

-

-

-

-

-

Loss on impairment of fixed assets

-

-48

-41

-

-

-

-

-

-

Warrant Modification

666

765

-

-

-

-

-

-

-

Derivatives loss

-

-11,400

-2,267

593

-10,804

-376

-18,871

17,480

-26,065

Gain on lease assignment

-

603

-

-

-

-

-

-

-

Non-cash interest expense

-

-

5

5

5

-

-

-

-

Common stock issued to 401(k) plan

-

-

-

-

-

173

-

-

-

Common stock issued for services

-

-

-

-

-

477

-

25

209

Non-cash interest expense

-

-

-

-

-

-

-

22

-

Non-cash loss from modification of warrants

-

-

-

-

-

-

765

-

-

Common stock issued to 401(k) plan

-

6

183

208

201

-

-

-

-

Common stock issued to 401(k) plan

-

-

-

-

-

-

192

92

41

Share-based compensation expense

268

618

4,106

5,063

4,666

2,730

3,136

1,233

921

Non-cash investment (income) expense, net

-1

-3

-

-98

-

-

-

-

-

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

-61

-180

-

54

547

Prepaid expenses

-267

-77

89

267

-888

363

-

-

12

Prepaid expenses

-

-

-

-

-

-

-124

61

-

Insurance receivable

-

-

-

-

-

689

-

-

-

Other assets

123

985

-321

324

-3

-4

-5

-

-

Other assets

-

-

-

-

-

-

-

-

125

Accounts payable

127

-173

-23

489

-48

-330

-254

585

230

Operating lease liability

-144

-

-

-

-

-

-

-

-

Accrued expenses and other liabilities

132

-136

-144

1,471

-279

-248

271

403

370

Non-cash disposals of property and equipment

-

-

-

-

-

45

-

-

-

Net cash used in operating activities

-10,314

-12,312

-19,683

-16,740

-16,329

-

-

-

-7,429

Cash flows from investing activities:
Purchases of marketable securities

-

-

8,256

-

-

-

-

-

-

Sales of marketable securities

-

-

19,833

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-15,284

-14,906

-10,204

-

Purchases of marketable securities

-

-

-

18,916

5,274

-

-

-

-

Sales of marketable securities

-

-

-

12,515

-

-

-

-

-

Purchases of property and equipment

12

65

65

107

5

47

749

2,141

278

Net cash used in investing activities

-12

-65

11,512

-6,508

-5,279

-

-

-

-278

Cash flows from financing activities:
Net cash (used in) provided by investing activities

-

-

-

-

-

-2

-749

-2,141

-

Proceeds from exercise of stock options

-

-

26

191

1,068

212

456

111

-

Proceeds from issuance of stock under ESPP

1

4

51

91

-

-

-

-

-

Proceeds from exercise of warrants

-

131

3

-

7,789

12

15,952

1,129

-

Principal payments on capital lease obligation

-

-

-

-

-

21

33

33

24

Repayment of loan payable

100

752

423

395

250

-

-

-

-

Proceeds from issuance of note payable

-

-

-

-

-

-

150

-

-

Proceeds from loan payable

-

-

-

-

-

-

342

1,747

151

Repayment of loan payable

-

-

-

-

-

-

-

303

17

Repayment of note payable

-

-

-

-

18

56

57

-

-

Repurchase of warrants

-

14

40

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants, net of commissions and issuance costs

367

16,511

-

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants

-

-

-

29,905

14,480

14,618

-

18,155

-

Net cash (used in) provided by financing activities

-

-

-

-

-

14,765

16,810

20,806

-

Increase (decrease) in cash and cash equivalents

-

-

-

-

-

-521

-

-

-

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

2,998

Net cash (used in) provided by financing activities

268

15,880

-383

29,792

23,069

-

-

-

3,108

Decrease in cash and cash equivalents and restricted cash

-10,058

3,503

-8,554

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents

-

-

-

6,544

1,461

-

1,155

8,461

-4,600

Supplemental disclosure of cash flow information and non-cash investing and financing activities:
Cash paid for interest

1

44

71

103

121

132

125

50

8

Fair value of warrants issued in connection with the 2020 Offering

59

-

-

-

-

-

-

-

-

Reclassification of derivative warrant liability to additional paid-in capital

-

-

-

-

16,121

-

-

-

-

Asset acquired through capital lease obligation

-

-

-

-

-

-

-

-

93

Fair value of warrants issued in connection with loan agreement

-

-

-

-

-

-

-

32

10

Non-cash issuance of common stock for warrants

-

287

3,537

90

251

-

-

-

-

Fair value of derivative warrant liability reclassified to additional paid-in capital

-

25,327

-

-

-

6,848

-

-

-

Right-of-use assets and lease liability recorded upon adoption of ASC 842

1,475

-

-

-

-

-

-

-

-

Reclassification of derivative warrant liability to additional paid-in capital

-

-

-

-

-

-

33,456

3,409

1,239